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Case report
Our patient’s history began 9 years ago, when he was 21. 
He presented to his primary care doctor for a regular 
checkup, with no complaints but with a past medical his-
tory of  ambylopia. Throughout this entire history, the pa-
tient denied smoking as well as living with a smoker or illicit 
drug use. He was occupied as a student, with no known 
environmental hazards at work or home. On physical ex-
amination he was found to have left-sided abdominal full-
ness, suspicious of  a mass. A hepatic function panel showed 
mildly elevated liver enzymes, suggestive of  hepatitis. A 
workup for the hepatitides came back negative. His primary 
medical doctor (PMD) recommended that he have an ab-
dominal sonogram, the results of  which were interpreted as  
diffuse hepatic fatty infiltration (Fig. 1). 
A few months later, the patient returned to the clinic for 
followup of  elevated liver enzymes, again with no com-
plaints. On physical examination he was found to have digi-
tal clubbing.  He did not return to the clinic for one year, 
after which time he returned complaining of  vague epigas-
tric pain. A chest x-ray was read as normal. A Holter moni-
tor and echocardiogram showed an ejection fraction of  
69%.  He had persistently elevated liver enzymes and un-
derwent computed tomography (CT)-guided liver biopsy. It 
revealed micro- and macro-vesicular steatosis, few fibrotic 
portal tracts, and focal bridging fibrosis, suggesting nonal-
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This report describes a case of  adult-onset cystic fibrosis (CF) in an African-American male. Although 
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the African-American population (1 in 17,000), with only Asian population ancestries being less affected 
than African blacks. We present our patient’s disease course in order to elucidate the manifestations of  
CF in this particular ethnic population. More specifically, this patient had a form of  CF with late-onset 
features, which may represent a new clinical phenotype of  CF. We seek to improve clinician awareness of 
CF disease subtypes. We also show the radiographic intra- and extra-thoracic manifestations of  CF and 
the peculiar clinical scenario that brought forth this condition. 
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Figure 1. 27-year-old African-American male with late-onset 
cystic fibrosis. Transabdominal ultrasound scan shows a 
highly echogenic liver (arrow) in comparison to adjacent 
right kidney (arrowhead).
coholic steatohepatitis (NASH), stage II (Fig. 2). He was 
started on ursodiol. At that time he also tested negative for 
antimitochondrial, smooth muscle, microsomal, and nu-
clear antibodies.
Later that year, he presented to his PMD with nasal dis-
charge, mild cough, and greenish sputum production. He 
was prescribed antibiotics and did not return to the clinic 
for almost two years, after which he returned with the same 
symptoms, in addition to frontal headaches. During this 
time he had undergone nasal endoscopy and polypectomy 
at an outside hospital. On his return, he received a head 
CT and was diagnosed with significant paranasal sinus dis-
ease and was prescribed prednisone. When his symptoms 
did not resolve after two months, maxillofacial CT was per-
formed (Fig. 3). Pansinusitis was observed, and fiberoptic 
endoscopic sinus surgery was recommended and 
completed.  
At this time, the patient was referred for a sweat chloride 
test, which revealed a chloride level of  106 mmol/L, diag-
nostic for CF. He went for followup genetic testing, which 
was sent out to Quest Diagnostics. The test was performed 
using a polymerase chain reaction, followed by oligonucleo-
tide ligation assay. Their panel included 23 allele mutations, 
as recommended by the American College of  Medical Ge-
netics. The patient tested negative for all allele mutations. 
He was referred for larger panel testing at an outside loca-
tion but did not follow up. After normal spirometry testing 
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Figure 2. 27-year-old African-American male with late-onset cystic fibrosis. High-powered light microscopy of the liver obtained 
from CT-guided biopsy (H+E stain). A) 10x view, macrovesicular fatty infiltrate (lipocytes, black arrowhead) and chronic portal 
inflammation (inflammatory cells, white arrows), characteristic of nonalcoholic steatohepatitis. B) 10x image shows portal in-
flammation again noted, with spill into liver parenchyma (interface of inflammation, arrows), also characteristic of hepatitis. C) 
and D) 10x and 40x views, respectively, of trichrome stain highlighting perivenular fibrosis (black arrows) and steatosis (white 
arrows).
and chest x-ray, the patient was given a diagnosis of  chronic 
cough secondary to postnasal drip.  
The following year, now at 24 years of  age, the patient 
returned with a worsening cough, producing gray sputum 
and nasal discharge. He was prescribed antibiotics. Also, 
with persistently abnormal liver cemistries, and a new de-
velopment of  hypoalbuminemia, a liver ultrasound re-
vealed normal liver with cholelithasis. He was continued on 
ursodiol. During the next three years, the patient repeated 
this cycle, with numerous serumchemistries performed, 
another ultrasound showing fatty liver, a biopsy demon-
strating steatosis involving 55% of  lobules, and pericellular 
fibrosis in perivenular areas. He also underwent workups 
for several syndromes including hypothyroidism, vasculiti-
des, angiotensin-converting enzyme (ACE) deficiency, hu-
man immunodeficiency virus (HIV), syphilis, iron and cop-
per metabolism abnormalities, and amyloidosis, all of  
which returned negative.
This year, the 27-year-old patient returned again with the 
same upper respiratory symptoms, and was found to have 
decreased oxygen saturation. A chest x-ray revealed diffuse 
reticular opacities. A chest CT revealed predominantly 
upper-lobe bronchiectasis, with diffuse tree-in-bud opacities  
(Fig. 4). Although the patient did not have gastrointestinal 
complaints, transient intussusception of  the small bowel 
was noted as well as dilation and severe fecal impaction 
within the large bowel (Fig. 5A). The pancreas was diffusely 
atrophic and showed marked fatty replacement (Fig. 5B). 
With continued abnormal liver lab results, he received sub-
sequent testing for alpha-1 antitrypsin deficiency and spu-
tum for tuberculosis, both of  which were negative. 
In worsening condition, our patient recently provided 
sputum for gram stain and culture. The gram stain showed 
gram-positive cocci in pairs, chains, and clusters, as well as 
gram-negative bacilli. The culture grew Pseudomonas fluo-
rescens, a rare bacterium documented in immunosup-
pressed individuals (1).  Immunofixation analyses also 
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Figure 4. 27-year-old African-American male with late-onset 
cystic fibrosis. Axial views of contrast-enhanced reformatted 
chest CT. A) Localized dilation of the bronchi reveals upper-
lobe bronchiectasis (arrow). Peribronchial cuffing demon-
strates extent of inflammation and mucous impaction. B) 
Tree-in-bud opacities appear within the lungs (arrow). Note 
the narrowed mediastinum.
Figure 3. 27-year-old African-American male with late-onset 
cystic fibrosis. Coronal view of reformatted maxillofacial CT, 
performed one year after endoscopic polypectomy. Image 
shows complete occlusion of the ostiomeatal complex 
(white arrow) and opacification of the sinuses. Heterogene-
ous attenuation of secretions within the maxillary sinus 
suggests trapped fluid centrally (asterisk). The ostia are 
markedly widened, with mucoid material extending into the 
nasal sinuses.
showed increased levels of  immunoglobulin G, sometimes 
associated with chronic infection.
It is clear that our patient suffers from an adult-onset 
form of  CF, with elevated sweat chloride level and no 
known CFTR mutation. To this day, our patient’s condition 
deteriorates, and he remains with no documented diagnosis 
of  CF. Insurance coverage for diagnostic testing generally 
follows nationally established health guidelines, which are 
designed to identify the disease in the vast majority of  
cases. However this strategy excludes coverage for new 
clinical profiles such as atypical CF, late-onset CF, and CF 
not testing positive against standard mutation and sweat 
chloride analyses.
Discussion
History and evolution of  CF
CF is a disease whose emerging new phenotypes have 
important implications for clinicians. After its first descrip-
tion in 1938, CF became known as an autosomal recessive 
illness, with an incidence of  approximately 1 in 3,000 
North Americans of  Caucasian origin (2).  Soon thereafter, 
it was revealed that elevated sweat chloride levels were a 
prominent feature of  the disease. This finding led to the 
development and implementation of  the diagnostic sweat 
chloride test for CF. Until the late 1980s, CF was associated 
with the classic clinical picture of  elevated sweat chloride 
levels, perinatal meconium ileus, early and recurrent lung 
infection, defective pancreatic secretion (leading to malab-
sorption, malnutrition, and pancreatic insufficiency), and 
absence of  the vas deferens in males. Predictably, these 
variable but progressive symptoms were found to lead to a 
shortened lifespan in CF patients (3). Later, with the discov-
ery of  the ΔF508 mutation on the cystic fibrosis transmem-
brane regulator (CFTR) gene, prenatal and postnatal 
screening was established, with the ΔF508 allele being the 
most frequent abnormal genotype. As more allele muta-
tions within the CFTR gene segments were discovered, 
screening panels were revised accordingly. 
Therapy improved for patients, namely pancreatic en-
zyme supplementation, more effective antibiotics specific 
for CF-related infections, and (more recently) gene therapy 
(4). Improved treatment regimens have considerably im-
proved morbidity and mortality for those suffering from CF, 
and have subsequently allowed a greater population of  CF 
to be studied (both in terms of  age range and clinical phe-
notype). The last decade of  research has suggested that the 
disease is widely varied in both genetic and phenotypic 
profiles, with a now-documented broad spectrum of  disease 
symptoms. Atypical CF, subacute disease, late-onset disease, 
and single-organ involvement have all been described (5). 
Over 1,700 allele mutations, polymorphisms, or unclassified 
variations of  the CFTR gene have been reported (6). Fur-
thermore, clusters of  groups other than Caucasians with 
CF-like symptoms are being examined for the presence of  
the disease, mostly African Americans and Hispanics in the 
United States. In this regard, allele mutations specific to 
clusters of  human populations have now been documented 
with the aim of  improving diagnostic efficacy within these 
population groups (7).
Current practice
Screening and diagnostic devices have been broadened 
over time to include these new disease subtypes. Intestinal 
current measurement, nasal potential difference, and im-
munoreactive trypsinogen (IRT) are examples of  tests used 
to predict CF in varied age groups, racial groups, and clini-
cal spectra. These new developments, however, have made 
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Figure 5. 27-year-old African-American male with late-onset 
cystic fibrosis. Axial views of the abdomen from contrast-
enhanced chest CT. A) The target sign is seen within the 
small bowel, indicating transient intussusception (arrow). 
The large bowel is dilated with severe fecal impaction (ar-
rowheads). B) Diffusely atrophic pancreas (arrows) is noted 
anterior to the left kidney demonstrating hyperattenuation 
secondary to fatty replacement. Also note decreased liver 
attenuation (L) as compared to the spleen (S).
even more apparent the complexity of  CF and the difficul-
ties of  approaching it. For example, while IRT has been the 
primary newborn screening tool in the past decade, it was 
recently shown to lead to a significantly disproportionate 
number of  false positives in the African-American popula-
tion (8). This illustrates the need for developing better diag-
nostic and assessment tools that can be applied to minority 
groups.
The gold standard for diagnosis remains a positive sweat 
chloride(Cl) test on two separate occasions, as defined by 
sweat Cl >60mmol/L. Despite this, the literature cites sev-
eral examples of  CF patients with borderline or normal 
sweat-chloride values (9). The finding of  two mutations in 
the CFTR gene is also diagnostic of  CF, though patients 
not testing positive for known mutations have been docu-
mented as well. Not all documented allele mutations are 
included in these testing panels; rather, each laboratory 
tests for frequently occurring mutations in the specific local 
population being served. In light of  the recent discoveries 
in CF, patients with undiagnosed symptoms, especially 
those with alternative symptomatology, or those of  non-
Caucasian origin, may want to pursue further testing be-
yond the routine tests being offered.  Other testing used for 
detection and monitoring of  disease progression are stool 
assays, sputum analysis, pulmonary function, and imaging 
techniques such as ultrasound, x-ray, and CT scan. 
Imaging
CF has several classic radiologic findings that have been 
studied over the years (10). Since CF is a progressive dis-
ease, imaging features are expected to change over a life-
time. For instance, the lungs are affected by abnormally 
viscous secretions that prevent proper clearance and pro-
mote bacterial growth. A chest x-ray in a baby or young 
child may be normal, but with age the typical findings of  
hyperaeration, peribronchial cuffing, increased linear 
opacities, and bronchiectasis become visibly apparent (11). 
Similarly, longstanding disease progression can result in the 
appearance of  a flattened diaphragm, mediastinal narrow-
ing, thoracic kyphosis, and sternal bowing. Finally, CT 
chest findings in children often reveal bronchiectasis, peri-
bronchial wall thickening, mosaic perfusion, and mucous 
plugging. Pan-sinus disease is also characteristic of  CF, due 
to thickened mucous, and nasal polyps are almost always 
present in the classic form of  the disease. Maxillofacial CT 
shows mucoceles, opacification of  the sinuses, and inflam-
matory changes as well (12.13). 
Hepatobiliary manifestations of  CF are typically less 
common than those of  the respiratory system, but with 
increased patient survival many clinicians have postulated 
that this will change. Imaging findings associated with he-
patic, biliary, and pancreatic involvement have been inves-
tigated more recently; although significant conclusions 
about the appearance of  long-term disease are less com-
mon. In almost 50% of  all cases, abdominal ultrasound of  
children with CF shows increased echogenicity of  the liver 
related to fatty infiltration, specifically in centrilobular and 
periportal regions. In abdominal CT, the liver may appear 
normal or show decreased attenuation, and many patients 
develop focal biliary cirrhosis, which can also be 
visualized. CT and magnetic resonance (MR) classically 
demonstrate progressive fatty replacement, dilated ducts, 
and eventual fibrosis and atrophy of  the pancreas (14). 
Gallbladder cholesterol stones are common and are best 
visualized on MR cholangiopancreatography (MRCP); mi-
crogallbladder has also been often noted (15). Bowel dys-
function leads to sequela manifesting on CT and MR as 
fecal impaction, colonic wall thickening, mural striation, 
mesenteric soft tissue infiltration, and increased pericolonic 
fat, predominantly in the right colon. 
Atypical CF
We have presented a unique case of  CF found in an 
African-American male with adult-onset features. While CF 
is common in North Americans of  European origin, the 
estimated incidence of  it is much lower in other ethnic 
groups, with African Americans representing 1 in 17,000 
new cases (2). Furthermore, the diagnosis of  CF has tradi-
tionally been made at birth or during early childhood. Our 
patient, however, presented with his first symptom of  CF at 
the age of  21. In the past several years, the clinical spec-
trum has widened with respect to age at presentation, eth-
nic background, severity of  disease, and extent of  organ 
involvement. Our patient’s CF exhibits two of  these newly 
emerging characteristics and thus provides a forum for dis-
cussing the need to expand our diagnosis and assessment 
approaches to this disease.
Although the medical records do not indicate a formal 
diagnosis of  CF in our patient, most likely due to his nega-
tive genetic testing, his slew of  imaging findings, sympto-
matology, laboratory results, and negative testing that ex-
cluded other diseases confirms and supports our current 
diagnosis. Regarding imaging findings, our patient had 
signs of  CF well before he complained of  any symptoms. 
At the age of  19, ultrasound tests found him to have idio-
pathic fatty liver, which has been cited as the most common 
hepatobiliary manifestation of  the disease (16). A later liver 
biopsy showed NASH; ultrasounds showed cholelithiasis 
and microgallbladder. Subsequent imaging after the onset 
of  symptoms were also highly suggestive of  CF, with classic 
manifestations such as pansinusitis on maxillofacial CT, and 
predominantly upper-lobe bronchiectasis, pancreatic atro-
phy, and severe fecal impaction on chest CT.
In addition to the patient’s appearance on imaging, his 
unexplained signs and symptoms also indicate CF, despite 
the fact that the age at presentation was later than usual. 
These included: difficulty breathing, nasal discharge, diffuse 
nasal polyps requiring surgery, recurrent cough with spu-
tum production, and frontal headaches. His physical exam 
findings were also characteristic of  CF: digital clubbing and 
decreased oxygen saturation. Although the patient’s imag-
ing reflected some gastrointestinal involvement, the patient 
did not have clear symptomatology related to this. This is in 
concert with recent evidence that cases of  adult-onset CF 
are milder and are largely associated with predominantly 
respiratory symptoms (17). These adult cases were further 
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shown to be associated with allele mutations other than the 
classic ΔF508, for which our patient also tested negative.
Positive and negative laboratory testing also supports a 
diagnosis of  CF in this patient. The most striking element 
of  his positive testing is the elevated sweat chloride level. 
Although this test was not repeated, his levels were well 
above normal and in the diagnostic range for CF. Further-
more, he underwent workup for other illnesses that could 
cause elevated sweat chloride, such as hypothyroidism, 
nephrogenic diabetes insipidus, and Addison’s disease, the 
results of  which were all negative. His persistently elevated 
hepatic enzymes reflect liver involvement and have been 
shown to be common in CF (18). Similarly, this patient’s 
gram stain showed Staphylococcus aureus and Pseudomo-
nas aeruginosa, organisms that have traditionally infected 
the lungs of  CF patients (19, 20). Sputum culture grew 
Pseudomonas fluorescens, a rare organism that has not 
been typically associated with CF, but documented to colo-
nize lungs of  immunosuppressed individuals with HIV (21).  
P. fluorescens colonization most likely represents our pa-
tient’s decreased immune function within the lungs, and 
may demonstrate a feature of  one or more emerging clini-
cal spectra of  CF. Negative laboratory tests performed in 
our patient include those for sickle cell disease, autoimmune 
disease, vasculitides, hepatitides, iron and copper metabo-
lism abnormalities, tuberculosis, HIV, syphilis, drug abuse, 
ACE-, alph-1 antitrypsin-, and complement deficiencies 
and amyloidosis. He was also tested extensively for liver 
disease and anemia, to no further avail.
His negative genetic testing for CF does not rule out the 
disease. The test of  23 disease-causing CFTR mutations 
performed on our patient had a 69% likelihood of  diagnos-
ing CF in the African-American population (22). It has 
been reported that only 50% of  CFTR mutations causing 
disease in African-Americans have been discovered. ΔF508 
is the most commonly occurring known allele mutation 
regardless of  race (with the exception of  the Ashkenazi 
population), but it is predicted that this only accounts for 
48% of  African-American allele mutations (23). Molecular 
data regarding allele mutations in African Americans is 
more extensive than that in African populations, with more 
than double the number of  disease-causing mutations dis-
covered. Research has demonstrated that in the United 
States it is difficult to identify CF mutations that are 
population-specific, which may be attributable to ethnic 
diversity, racial admixture, and the wide range of  genetic 
profiles. A 2001 study, which genotyped 202 African-
Americans with CF, found that the standard mutation panel 
would have missed 1 in 7 subjects (24), and proposed ex-
panded mutation panels. In the case of  our patient, his 
insurance plan did not cover further genetic testing with a 
larger mutation panel outside our institution. His lack of  
genetic evidence for CF seems to have prevented him from 
being diagnosed with and treated for CF.
Conclusion
The confusion in assessing a proper diagnosis in our pa-
tient over the years was likely due to his rare CF “profile.” 
Despite the fact that his constellation of  signs and symp-
toms were classic for CF, he is of  African-American back-
ground and presented at a much later age than usual. Un-
derdiagnosis in non-Caucasian patients leads to difficulty in 
determining the impact of  CF on this particular population 
group. Additionally, further characterization of  the broad 
spectrum of  clinical appearances now associated with CF is 
required, such as that related to CF with pancreatic spar-
ing, single organ involvement, and late-onset disease. Edu-
cation of  health personnel about the emerging clinical pro-
files and ethnic backgrounds of  CF patients can lead to 
improved detection of  symptoms and referral for proper 
testing. 
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